Indiana SB 282, the first US med spa law, took effect July 1, 2026: state registration, a supervising practitioner, and 15 day adverse event reporting.
Indiana Senate Bill 282, the first comprehensive US med spa law, took effect July 1, 2026. It requires med spas to register with the state, name a responsible supervising practitioner, report adverse events within 15 days, and deliver injectables only at registered locations, effectively ending mobile pop up injectors.
Indiana has enacted what legal analysts describe as the first comprehensive medical spa statute in the United States. Senate Bill 282, enacted earlier in 2026, took effect on July 1, 2026, and pulls medical spas out of general medical practice rules into a dedicated registration and oversight framework run by the Indiana Medical Licensing Board.
The law reaches beyond aesthetic clinics. It also covers IV hydration bars, weight loss practices that dispense GLP-1 medications, and other facilities that provide medical treatments while marketing wellness, longevity, or beauty services. For patients, the headline change is simple: the person injecting you, and the place they do it, must now be on record with the state.
SB 282 sets four core obligations. First, every medical spa must register with the Indiana Medical Licensing Board, with the registration deadline set for January 1, 2027, after the board finalizes its rules. Second, each facility must name a responsible supervising practitioner, a physician, nurse practitioner, or physician assistant, who is accountable for clinical oversight and listed on the public record. Third, facilities must report qualifying adverse events within 15 days. Fourth, the law restricts where treatments may be delivered: services must occur at the registered clinical location, with narrow exceptions, which effectively ends mobile and pop up injector models. The board is also directed to maintain a public database of registered med spas so consumers can verify a clinic before booking.
Aesthetic injectables carry real, sometimes serious, risks. Botulinum toxin products such as Botox and Dysport are FDA approved for specific cosmetic and medical uses, and hyaluronic acid dermal fillers are FDA cleared, yet complications like vascular occlusion, infection, and misplaced product can cause lasting harm when a treatment is performed without proper training or supervision. GLP-1 weight loss drugs are FDA approved for their labeled indications, but compounded versions and off label cosmetic use fall outside that approval and add further risk. Until now, Indiana med spas operated largely under general medical practice rules, with no dedicated registry and no standard way for a patient to confirm who was supervising care. By naming a responsible practitioner, requiring a fixed clinical location, and creating a searchable state database, SB 282 gives patients verifiable signals that were previously unavailable, and it sets a template other states are watching.
The statute took effect July 1, 2026, but much of the operational detail still depends on rulemaking by the Indiana Medical Licensing Board, expected before the January 1, 2027 registration deadline. Open questions include how much on site presence a responsible practitioner must provide, how registration applies to rented or co owned spaces, and the exact adverse event reporting form. Texas, California, New Jersey, and Florida are advancing their own med spa measures in 2026, so Indiana's approach may shape a broader national standard. Patients in Indiana can expect registration status and supervising practitioner details to become part of how they vet a clinic.